Literature DB >> 10215997

Neuronal accumulation of poly(ADP-ribose) after brain ischaemia.

S Love1, R Barber, G K Wilcock.   

Abstract

Animal and in vitro studies suggest that overactivation of poly(ADP-ribose) polymerase (PARP) in response to oxidative DNA damage makes a substantial contribution to cell death after brain ischaemia. We have recently shown that global brain ischaemia due to cardiac arrest in man induces a rapid increase in the amount of neuronal and glial PARP that can be detected by immunohistochemistry. In the present study we sought evidence of a corresponding increase in the amount of poly(ADP-ribose) within the brain, as this would confirm PARP activation and imply resulting consumption of NAD+. We also studied the distribution of poly(ADP-ribose) accumulation in relation to morphological evidence of ischaemic damage, and used double immunolabelling to investigate the types of cell that were affected. We found that global brain ischaemia did cause accumulation of poly(ADP-ribose), particularly during the first 2 days after cardiac arrest. The distribution of cells with accumulation of poly(ADP-ribose) corresponded in general to regions of ischaemic damage or immediately adjacent neocortex. Double immunolabelling for poly(ADP-ribose) and MAP2 showed many of the cells with poly(ADP-ribose) accumulation to be neurons. Our findings are in keeping with experimental evidence of a role for PARP in post-ischaemic necrosis and of the potential for reducing ischaemic brain damage by the use of PARP inhibitors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10215997     DOI: 10.1046/j.1365-2990.1999.00179.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  17 in total

Review 1.  One path to cell death in the nervous system.

Authors:  J Glasgow; R Perez-Polo
Journal:  Neurochem Res       Date:  2000-10       Impact factor: 3.996

Review 2.  Oxidative stress and NAD+ in ischemic brain injury: current advances and future perspectives.

Authors:  W Ying; Z-G Xiong
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

Review 3.  Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities.

Authors:  Amos A Fatokun; Valina L Dawson; Ted M Dawson
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

4.  Permeability transition pore-dependent and PARP-mediated depletion of neuronal pyridine nucleotides during anoxia and glucose deprivation.

Authors:  Sibel Kahraman; Alex Siegel; Brian M Polster; Gary Fiskum
Journal:  J Bioenerg Biomembr       Date:  2014-10-24       Impact factor: 2.945

Review 5.  Pathophysiological Role of Peroxynitrite Induced DNA Damage in Human Diseases: A Special Focus on Poly(ADP-ribose) Polymerase (PARP).

Authors:  Badar Ul Islam; Safia Habib; Parvez Ahmad; Shaziya Allarakha; Asif Ali
Journal:  Indian J Clin Biochem       Date:  2015-01-20

6.  Poly(ADP-ribosyl)ation basally activated by DNA strand breaks reflects glutamate-nitric oxide neurotransmission.

Authors:  A A Pieper; S Blackshaw; E E Clements; D J Brat; D K Krug; A J White; P Pinto-Garcia; A Favit; J R Conover; S H Snyder; A Verma
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

Review 7.  Delayed cell death signaling in traumatized central nervous system: hypoxia.

Authors:  Danielle Chu; JingXin Qiu; Marjorie Grafe; Roderick Fabian; Thomas A Kent; David Rassin; Olivera Nesic; Karin Werrbach-Perez; Regino Perez-Polo
Journal:  Neurochem Res       Date:  2002-02       Impact factor: 3.996

Review 8.  Pathogenesis of malaria and clinically similar conditions.

Authors:  Ian A Clark; Lisa M Alleva; Alison C Mills; William B Cowden
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

Review 9.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

Review 10.  Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease.

Authors:  Pal Pacher; Csaba Szabo
Journal:  Am J Pathol       Date:  2008-06-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.